CG Oncology, Inc. (CGON) is a late-stage clinical biopharmaceutical company developing cretostimogene grenadenorepvec, an intravesically delivered oncolytic immunotherapy, as a bladder-sparing treatment for non-muscle invasive bladder cancer (NMIBC). Shares closed Friday at $74.40 and were last changing hands at $85.79, a gain of 15.31%, after the company reported that PIVOT-006 met its primary endpoint. The direction is unambiguously higher and the catalyst is verified: the release crossed the wire before Monday's opening bell, and the stock remains well above its prior 52-week high of $80.97 despite trading nearly $20 below its premarket peak.
The pivotal readout is the whole story. In PIVOT-006, 367 patients with intermediate-risk and high-grade Ta tumors of 3 cm or less received adjuvant cretostimogene or underwent surveillance after complete tumor resection. Cretostimogene reduced the risk of recurrence by 68%, with a hazard ratio of 0.32 (95% CI: 0.23–0.45; p<0.0001) at a median follow-up of 17 months. No Grade 3 or higher treatment-related adverse events and no treatment-related discontinuations were reported.
The magnitude, not merely the statistical significance, drove the repricing. The trial was powered for roughly a 30% reduction in recurrence risk, and investors had generally penciled in something near 40%. A 68% effect cleared even the most bullish scenarios, and the company notes that this roughly 50,000-patient U.S. population has no FDA-approved adjuvant therapy. Management described the result as positioning cretostimogene as the first candidate to show a significant recurrence benefit in a pivotal Phase 3 trial in this setting.
Sell-side commentary reinforced the move. RBC Capital Markets analyst Leonid Timashev wrote that the data meaningfully exceeded both the trial's powering assumptions near 30% and investor expectations near 40%, noting that even in the firm's most constructive conversations, investors had not anticipated a reduction above 50%. He also argued the trial's history of enrollment delays likely reflected the drug's outperformance rather than operational problems, and flagged the non-chemotherapy profile as a potential commercial advantage over JNJ's Inlexzo. That framing turned a single dataset into a competitive-positioning argument on Monday.
The intraday pattern is instructive. Shares touched $105.50 in premarket trading, opened at $92.00, and dropped to a session low of $80.75 within the first ten minutes before stabilizing. The offsetting item was regulatory timing: based on FDA feedback, CG Oncology will broaden its initial BLA in BCG-unresponsive NMIBC to include high-grade papillary-only disease, pushing completion from the fourth quarter of 2026 to before the end of March 2027. A second BLA from PIVOT-006 is targeted for the second quarter of 2027. The three-month slip is modest against a materially larger label, but it gave momentum traders a reason to book gains after a stock that had already risen about 79% year to date.
Participation was exceptional. Roughly 3.7 million shares had traded by mid-afternoon, versus a three-month average daily volume of about 1.0 million, comfortably more than triple normal turnover. The move was also sharply divergent from its backdrop: the S&P 500 fell about 1.9%, the biotech complex tracked by the XBI ETF dropped roughly 2.5%, and JNJ slipped nearly 1%. In other words, there was no sector or macro tailwind — the gain was entirely idiosyncratic.
Technically, the session delivered a gap-and-breakout above the prior 52-week high of $80.97 and the $37.01–$80.97 range that had contained the stock for a year. Holding above that former ceiling into the close would confirm the breakout; failure to do so would leave Monday's gap as an open question. Market capitalization now sits near $7.6 billion.
The scale runs from 0, meaning no meaningful news and a routine move for the stock, to 100, meaning transformative news and an extreme, rare price move. This event scores 82 out of 100.
The news component is strong: a pivotal Phase 3 registrational trial met its primary endpoint with an effect roughly double the market's bar, in an indication with no approved therapy, and with clean safety. The price component is nearly as strong. Today's 15.31% advance is about 6.4 times the stock's average absolute daily move of roughly 2.4% over the past 60 sessions, and only one of those sessions produced a larger swing — the 17.3% gain on November 6. A pivotal win paired with a rare, high-volume move lifts the combined score into the low 80s rather than the 90s, since the filing delay and the fade from premarket highs trimmed the upside.
The near-term calendar is dense. Full PIVOT-006 results will be presented as a late-breaking podium session at the Society of Urologic Oncology annual meeting on December 2, 2026, where investors will parse the high-grade versus low-grade contribution to the benefit. December also brings 12-month data from BOND-003 Cohort P and CORE-008 Cohort CX. On the regulatory side, completion of the BCG-unresponsive BLA is now targeted before the end of March 2027, with the PIVOT-006 filing in the second quarter of 2027; all BLA-enabling manufacturing work is complete, and roughly $984.5 million in cash is expected to fund operations through 2029. Fourth-quarter and full-year results are due in early 2027.
Risks cut both ways. The data so far are topline, the comparator was surveillance rather than an active agent, and the shares entered Monday after a long run. Any suggestion that the benefit concentrates in lower-grade patients, or a further slip in filing timing, would test the new valuation. Rivals including JNJ are also advancing in NMIBC, and commercial execution remains untested.
Tickeron operates hundreds of AI trading bots spanning thousands of tickers, but its Trending AI Robots page curates only the strongest performers under current market conditions. Bots differ widely by strategy, timeframe, performance metrics and traded symbols, so the featured roster shifts as volatility and leadership rotate. For readers tracking catalysts like Monday's clinical readout, it offers a structured way to see which automated approaches are working now. Reviewing the current lineup is a practical next step.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CGON moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend. In 28 of 30 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on CGON as a result. In 40 of 49 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for CGON just turned positive on October 22, 2026. Looking at past instances where CGON's MACD turned positive, the stock continued to rise in 25 of 29 cases over the following month. The odds of a continued upward trend are 86%.
The 10-day moving average for CGON crossed bullishly above the 50-day moving average on November 11, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 11 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 82%.
Following a +20.86% 3-day Advance, the price is estimated to grow further. Considering data from situations where CGON advanced for three days, in 119 of 149 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The Aroon Indicator entered an Uptrend today. In 89 of 99 cases where CGON Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 34 of 39 cases where CGON's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 87%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CGON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
CGON broke above its upper Bollinger Band on November 16, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Valuation Rating of 13 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.545) is normal, around the industry mean (3.586). P/E Ratio (-28.249) is within average values for comparable stocks, (-1.188). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1000.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. CGON’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 58 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CGON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology